Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Ref Type Abstract
Authors Yongqiang Zhu; Jia Wang; Minghong Shang
Title Abstract LB330: FHND5071: a selective RET inhibitor with unique pharmacokinetic profile
Abstract Text Background: Gene rearrangements (fusions) and mutations in RET have the potential to be oncogenic drivers and have been observed in a variety of tumors types. Selective RET inhibitors selpercatinib and pralsetinib have been approved for patients with RET-altered cancers. FHND5071 is a novel kinase inhibitor which specifically targets RET activated forms and has unique pharmacokinetic profile. Methods: The pharmacological profile of FHND5071 have been confirmed in in vitro and in vivo evaluations, including enzyme and cell-based assays, PK/PD study, and RET-dependent tumor models. Results: In enzymatic assays, FHND5071 potently inhibited RET wild type, RET fusions and mutations with the IC50 of 4.47~19.26 nM and demonstrated 89-fold selectivity over KDR (VEGFR-2). FHND5071-M2, the active metabolite identified in pre-clinical pharmacokinetics, had the same potency as FHND5071. In cellular settings, FHND5071 inhibited the proliferation of Ba/F3 engineered cells (RET WT, RET V804M, RET M918T) and inhibited RET phosphorylation in HEK-293 engineered cells (WT, V804M, RET M918T, KIF5B-RET, CCDC6-RET) with the similar potency compared with selpercatinib. In PK/PD study (Ba/F3 KIF5B-RET allograft model), compared with selpercatinib, FHND5071 had longer Tmax and MRT in plasma and tumor tissue. FHND5071 preferred to be distributed into tissues. The exposure of FHND5071 in tumor tissue (AUC0-t) was ~28 times that of selpercatinib and the concentration of FHND5071 in brain tissue was ~33 times that of selpercatinib at 4 h after dosing. Meanwhile, after FHND5071 administration, RET phosphorylation and the downstream signaling protein (pAKT, pErk1/2) were significantly inhibited in tumor tissue and the inhibition was maintained for 24 h at least. But the duration of inhibition with selpercatinib was shorter than that of FHND5071. In tumor models, FHND5071 exhibited significant anti-tumor efficacy in Ba/F3 KIF5B-RET model at oral dose levels ≥3 mg/kg once daily (QD) without inducing significant toxicity. FHND5071 QD exhibited similar anti-tumor activity as selpercatinib administrated twice a day (BID) at 30 mg/kg. 30 mg/kg FHND5071 (QD) demonstrated significant anti-tumor efficacy with 100% TGI in patient-derived xenograft models (colorectal cancer with CCDC6-RET and ovarian cancer with NCOA4-RET). In CCDC6-RET intracranial xenograft model, 30 mg/kg FHND5071 (QD) significant prolonged life time of model mice. The median survival time was 56 days and the increase in life-span was 51% (p<0.005 compared with the vehicle group). Conclusions: FHND5071 demonstrated excellent selectivity and anti-tumor efficacy. The unique pharmacokinetic profile of FHND5071 supported the frequency of once-a-day dosing and better efficacy in target organ and brain tumor in clinical. FHND5071 has received IND approval from NMPA and FDA. It is currently in the dose-escalation segment of a first-in-human phase 1 trial for patients with RET-driven solid tumors.


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
FHND5071 FHND5071 2 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
FHND5071 FHND 5071|FHND-5071 RET Inhibitor 52 FHND5071 inhibits RET, which decreases downstream signaling and potentially results in reduced cell proliferation and tumor growth (Cancer Res (2023) 83 (8_Supplement): LB330).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET M918T Advanced Solid Tumor predicted - sensitive FHND5071 Preclinical - Cell culture Actionable In a preclinical study, FHND5071 inhibited Ret phosphorylation and proliferation in cells expressing RET M918T in culture (Cancer Res (2023) 83 (8_Supplement): LB330). detail...
RET V804M Advanced Solid Tumor predicted - sensitive FHND5071 Preclinical - Cell culture Actionable In a preclinical study, FHND5071 inhibited Ret phosphorylation and proliferation in cells expressing RET V804M in culture (Cancer Res (2023) 83 (8_Supplement): LB330). detail...